ZyVersa Therapeutics FY 2023 Financial Performance and Cash Expectations
Monday, 25 March 2024, 20:07
ZyVersa Therapeutics Financial Report Overview
The financial results reveal a GAAP EPS of -$0.29 for ZyVersa Therapeutics in FY 2023. The company's anticipated cash position by December 31, 2023 is $3.1 million, highlighting financial challenges ahead.
Key Points:
- GAAP EPS: -$0.29
- Expected Cash: $3.1 million
Shareholders and investors should pay close attention to ZyVersa's financial strategies for improving performance and maintaining liquidity during this period of financial uncertainty.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.